TY - JOUR T1 - Synthesis of poly (amidoamine) (PAMAM) dendrimer-based chitosan for targeted drug delivery and cell therapy TT - JF - Ilam-University-of-Medical-Sciences JO - Ilam-University-of-Medical-Sciences VL - 5 IS - 4 UR - http://jbrms.medilam.ac.ir/article-1-381-en.html Y1 - 2018 SP - 6 EP - 13 KW - PAMAM dendrimer KW - Fe3O4 KW - Trimethylchitosan KW - Cytotoxicity KW - Magnetic KW - Drug delivery N2 - Introduction: In the current study we designed a sophisticated drug delivery nanoparticle to control the methylprednisolone succinate delivery rate and affect the cancer cell growth in culture condition. Materials and methods: Magnetic nanoparticles were synthesized through co-precipitation method. Fe3O4 was first prepared via co-precipitation method and then its surface was functionalized with polyamidoamine (PAMAM) nanodendrimer. PAMAM synthesis trait was detected via FT-IR and SEM methods. Methylprednisolone drug was loaded on PAMAM@Fe3O4 and its effect against cancer cell lines was studied. In order to slow down drug release rate from nanoparticles, PAMAM@Fe3O4 were coated with trimethylchitosan (TMC) after drug loading. Performance of PAMAM@Fe3O4@TMC nanoparticles loaded with mmethylprednisolone, were evaluated against two cell lines to detect the cytotoxic and apoptotic effects by invert light scanning microscopy, immunoassay, and LDH cytotoxicity Kit. Results: According to SEM, image size of Fe3O4 was 4.79-6.37nm, which is smaller than nanodendrimer (6.30-43.67 nm). FT-IR spectrum for ester bond Methylacrylate @ Ethylendiamin was obtained to be 1720-1730 cm-1. FT-IR Spectrums 600 cm-1, 1000 cm-1 belong to Fe3O4, and Fe3O4@ NH2. Also, trimethyl chitosan coated Nanoparticle @ Drug, smearing trimethyl chitosan with Glutaraldehyde, created cross link between TMC monomer at low drug doses in each complete nanoparticle, gave confidence drug side effect, therefore, this nanoparticle could be safe for future cancer therapy. Conclusion: The results showed that drug delivery via PAMAM@Fe3O4 nanoparticle reduces cell viability in vitro condition. M3 10.29252/jbrms.5.4.6 ER -